April 2004
Gut;Apr2004 Supplement 3, Vol. 53, pA82
Academic Journal
Clinical trials suggest treating genotype 1 hepatitis C with combination treatment for 12 months and genotype 2/3 for 6 months. However, this prolonged course of treatment reduces compliance and puts enormous strain on budgets, thereby limiting its use. This study has shown that 3 months treatment may be adequate for patients with genotype 2/3 hepatitis C; however the higher role of relapse in genotype 1 may indicate the need for 6-12 months combination therapy.


Related Articles

  • Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment-Naive Subjects. Bartels, Doug J.; Yi Zhou; Zhang, Eileen Z.; Marcial, Michelle; Byrn, Randal A.; Pfeiffer, Thomas; Tigges, Ann M.; Adiwijaya, Bambang S.; Chao Lin; Kwong, Ann D.; Kieffer, Tara L. // Journal of Infectious Diseases;9/15/2008, Vol. 198 Issue 6, p800 

    Background. The prevalence and clinical implications of naturally occurring variants that are resistant to hepatitis C virus (HCV) protease inhibitors in treatment-naive patients has not been reported. We report here the prevalence of such variants and their effect on clinical response. Methods....

  • Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells. El Awady, Mostafa K.; El Din, Noha G. Badr; El Garf, Wael T.; Youssef, Samar S.; Omran, Moataza H.; El Abd, Jasmin; Goueli, Said A. // Cancer Cell International;2006, Vol. 6, p18 

    Background: Hepatitis C (HCV) viral infection is a serious medical problem in Egypt and it has a devastating impact on the Egyptian economy. It is estimated that over 15% of Egyptians are infected by the virus and thus finding a cure for this disease is of utmost importance. Current therapies...

  • CLINIC ROUNDUP.  // BioWorld Today;10/30/2008, Vol. 19 Issue 212, p6 

    This section offers news related to clinical trials. Dosing of ANA598 in patients chronically infected with hepatitis C virus has been started by Anadys Pharmaceuticals Inc. in a Phase Ib study. Enrollment has been completed in Chelsea Therapeutics International Limited's Phase II trial...

  • Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Spada, E.; Mele, A.; Berton, A.; Ruggeri, L.; Ferrigno, L.; Garbuglia, A. R.; Perrone, M. P.; Girelli, G.; Del Porto, P.; Piccolella, E.; Mondelli, M. U.; Amoroso, P.; Cortese, R.; Nicosia, A.; Vitelli, A.; Folgori, A. // Gut;Nov2004, Vol. 53 Issue 11, p1673 

    Background/Aims: Hepatitis C virus (HCV) infection results in a high frequency of chronic disease. The aim of this study was to identify early prognostic markers of disease resolution by performing a comprehensive analysis of viral and host factors during the natural course of acute HCV...

  • Reemergence of Hepatitis C Virus after 8.5 Years in a Patient with Hypogammaglobulinemia: Evidence for an Occult Viral Reservoir. Lee, William M.; Polson, Julie E.; Carney, D. Spencer; Sahin, Bogachan; Gale, Jr., Michael // Journal of Infectious Diseases;9/15/2005, Vol. 192 Issue 6, p1088 

    The question of whether viruses persist after apparent clearance of infection remains unanswered. Here, we describe a patient with hypogammaglobulinemia whose acute hepatitis C virus (HCV) infection appeared to resolve after receipt of interferon therapy, relapse immediately, and then clear...

  • ANA773.  // Biotech Financial Reports;Sep2009, Vol. 16 Issue 9, p8 

    The article offers information on the phase I clinical trial of ANA773, an oral inducer of endogenous interferons acting via the toll like receptor 7 pathway, by Anadys Pharmaceuticals Inc. in San Diego, California. It notes the company' report of evidence of viral load reduction in the majority...

  • Strategy for randomised clinical trials in rare cancers. Say-Beng Tan; Dear, Keith B. G.; Bruzzi, Paolo; Machin, David // BMJ: British Medical Journal (International Edition);7/5/2003, Vol. 327 Issue 7405, p47 

    Discusses a strategy for randomised clinical trials in rare cancers. Need for randomised trials to establish that treatments are effective; Problems of small trials; Designing a new trial; Prior and posterior distribution.

  • Dispelling the Myths: Calling for Sex-Specific Reporting of Trial Results. Hayes, Sharonne N.; Redberg, Rita F. // Mayo Clinic Proceedings;May2008, Vol. 83 Issue 5, p523 

    The author reflects on the exception of women from clinical trials. He states that understanding the sex-based difference is important in developing new approaches to prevention, diagnosis, and intervention. He added that analyzing data by sex for conditions or treatments affecting both genders...

  • Flow Diversion in Aneurysms Trial: the Design of the FIAT study. RAYMOND, J.; DARSAUT, T. E.; GUILBERT, F.; WEILL, A.; ROY, D. // Interventional Neuroradiology;jun2011, Vol. 17 Issue 2, p147 

    Intracranial aneurysms, particularly large and giant, fusiform or recurrent aneurysms are increasingly treated with flow diverters (FDs), a recently introduced and approved neurovascular device. While some rare cases may not be treated any other way, in most patients a more conventional,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics